Updated time: 2024-04-01 15:00:14
28A-1090420
2021-07-02
US 11,332,490 B1 、JP 7337111、、TW I834951
Disclosed herein are substrates and/or inhibitors of endo-O-sulfatase 1 (Sulf-1) that can be the methods of identifying and treating a subject having or suspected of having osteoarthritis. The method includes steps of (a) mixing a urine sample of the subject with 4-methylumbelliferyl sulfate (4-MUS) and a Sulf-1 inhibitor of formula (I) or (II); (b) determining a fluorescence intensity of the mixture of the step (a); and (c) treating the subject with an analgesic, a non-steroidal anti-inflammatory drug (NSAID), or a corticosteroid when the determined fluorescence intensity of the step (b) is smaller than that of a control sample, which is a mixture of the urine sample and 4-MUS.
- Non-invasion form.
- The high sensitivity to early stage of osteoarthritis (OA).
- No exposure to radiation of traditional radiography, for example, X-ray imaging.
- The new formula of glu-mix can not only promote extracellular matrix synthesis but also maintain chondro-properties.
- The endo-sulfatase inhibitors have been developed, in which the synthesized compound would be the best inhibitor towards Sulf1 when compared with reported inhibitors in the literature.
- To identify the stages of OA.
- To comment the health of knee.
- To evaluate the effectiveness of OA therapy.
- To establish the small animal model system.

Fig1. The structure of substrate for endo-O-sulfatase 1 (Sulf-1) inhibitors.

Fig2. Characterization of the binding kinetics of compound 46 with hSulf1d417−726 by surface plasmon resonance (SPR).
Shang-Cheng Hung、Chi-Huey Wong、Ting-Jen Cheng
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

COMPOUNDS AND METHODS FOR TREATING OSTEOARTHRITIS